Scitara Corporation is merging best aspects of contemporary cloud-based systems with a publicly owned platform that has high level security and laboratory-specific serviceability. Scitara DLX increases the speed of retrieving and distributing data, increasing scientific productivity and helping make recommendations based on scientific insights. The Scitara DLX platform is said to allow new stages of data transfer and mechanisation, and change the basis of lab integration.
Scitara CEO, Ajit Nagral expressed “The life sciences industry faces unusual survival challenges today in terms of accelerating time to market to remain competitive in a heavily regulated environment. Modern laboratories find themselves today in a digital transformation journey. With Scitara DLX, our vision has been to embrace the diversity in today’s laboratory, enable universal connectivity so no instrument or application is left behind, and ensure seamless integration across best-of-breed solutions. By providing a cloud-native platform, scientists can not only free up more time for science, but also leverage AI/ML techniques, data analytics, and decision-making tools, to more effectively develop life-saving therapies, novel biologics and vaccines.”
“Our goal is to enable modern, plug-and-play connectivity for any laboratory device, application or service using the Scitara DLX“
Scitara CTO, Geoff Gerhardt, said “Our goal is to enable modern, plug-and-play connectivity for any laboratory device, application or service using the Scitara DLX backbone to engage in multi-directional data exchange between multiple end points in the lab. We have created an open system that ensures equal advantage to every connection on the DLX platform, enabling instrument and application vendors as well as customers to have access to hundreds of available connectors and out-of-the-box workflow orchestrations, or utilize our tools to write their own connectors and orchestrations for use within the platform. Our scalable SaaS offering makes it possible for the smallest of labs to the largest of scientific enterprises to easily afford and adopt our platform.”